Work

Association of endopeptidases, involved in SARS‐CoV‐2 infection, with microbial aggravation in sputum of severe asthma

Year: 2021

Type: article

Abstract: AllergyVolume 76, Issue 6 p. 1917-1921 LETTER TO THE EDITOROpen Access Association of endopeptidases, involved in SARS-CoV-2 infection, with microbial aggravation in sputum of severe asthma Mahmoud I. Abdel-Aziz, Mahmoud I. Abdel-Aziz orcid.org/0000-0001-9263-7137 Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, EgyptSearch for more papers by this authorNazanin Zounemat Kermani, Nazanin Zounemat Kermani Data Science Institute, Imperial College London, London, UKSearch for more papers by this authorAnne H. Neerincx, Anne H. Neerincx Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorSusanne J. H. Vijverberg, Susanne J. H. Vijverberg Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorYike Guo, Yike Guo Data Science Institute, Imperial College London, London, UKSearch for more papers by this authorPeter Howarth, Peter Howarth NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, University of Southampton, Southampton, UKSearch for more papers by this authorSven-Erik Dahlen, Sven-Erik Dahlen Centre for Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenSearch for more papers by this authorRatko Djukanovic, Ratko Djukanovic NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, University of Southampton, Southampton, UKSearch for more papers by this authorPeter J. Sterk, Peter J. Sterk Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorAletta D. Kraneveld, Aletta D. Kraneveld Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands Faculty of Veterinary Medicine, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The NetherlandsSearch for more papers by this authorAnke H. Maitland-van der Zee, Anke H. Maitland-van der Zee Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands Department of Pediatric Respiratory Medicine, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The NetherlandsSearch for more papers by this authorKian Fan Chung, Kian Fan Chung orcid.org/0000-0001-7101-1426 National Heart and Lung Institute, Imperial College London, and Royal Brompton and Harefield NHS Trust, London, UKSearch for more papers by this authorIan M. Adcock, Corresponding Author Ian M. Adcock [email protected] orcid.org/0000-0003-2101-8843 National Heart and Lung Institute, Imperial College London and the NIHR Imperial Biomedical Research Centre, London, UK Correspondence Ian M. Adcock, National Heart and Lung Institute, Imperial College London and the NIHR Imperial Biomedical Research Centre, London, UK. Email: [email protected]Search for more papers by this authorOn behalf the U-BIOPRED Consortium, On behalf the U-BIOPRED ConsortiumSearch for more papers by this author Mahmoud I. Abdel-Aziz, Mahmoud I. Abdel-Aziz orcid.org/0000-0001-9263-7137 Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands Department of Clinical Pharmacy, Faculty of Pharmacy, Assiut University, Assiut, EgyptSearch for more papers by this authorNazanin Zounemat Kermani, Nazanin Zounemat Kermani Data Science Institute, Imperial College London, London, UKSearch for more papers by this authorAnne H. Neerincx, Anne H. Neerincx Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorSusanne J. H. Vijverberg, Susanne J. H. Vijverberg Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorYike Guo, Yike Guo Data Science Institute, Imperial College London, London, UKSearch for more papers by this authorPeter Howarth, Peter Howarth NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, University of Southampton, Southampton, UKSearch for more papers by this authorSven-Erik Dahlen, Sven-Erik Dahlen Centre for Allergy Research, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, SwedenSearch for more papers by this authorRatko Djukanovic, Ratko Djukanovic NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, University of Southampton, Southampton, UKSearch for more papers by this authorPeter J. Sterk, Peter J. Sterk Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsSearch for more papers by this authorAletta D. Kraneveld, Aletta D. Kraneveld Division of Pharmacology, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands Faculty of Veterinary Medicine, Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The NetherlandsSearch for more papers by this authorAnke H. Maitland-van der Zee, Anke H. Maitland-van der Zee Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands Department of Pediatric Respiratory Medicine, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The NetherlandsSearch for more papers by this authorKian Fan Chung, Kian Fan Chung orcid.org/0000-0001-7101-1426 National Heart and Lung Institute, Imperial College London, and Royal Brompton and Harefield NHS Trust, London, UKSearch for more papers by this authorIan M. Adcock, Corresponding Author Ian M. Adcock [email protected] orcid.org/0000-0003-2101-8843 National Heart and Lung Institute, Imperial College London and the NIHR Imperial Biomedical Research Centre, London, UK Correspondence Ian M. Adcock, National Heart and Lung Institute, Imperial College London and the NIHR Imperial Biomedical Research Centre, London, UK. Email: [email protected]Search for more papers by this authorOn behalf the U-BIOPRED Consortium, On behalf the U-BIOPRED ConsortiumSearch for more papers by this author First published: 07 January 2021 https://doi.org/10.1111/all.14731Citations: 1 Mahmoud I. Abdel-Aziz acd Nazanin Zounemat Kermani: Shared co-authorship Funding information U-BIOPRED has received funding from the Innovative Medicines Initiative (IMI) Joint Undertaking under grant agreement no. 115010, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007–2013), and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in-kind contributions (www.imi.europa.eu). AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor, COVID-19 can be a serious multisystem disease caused by the SARS-CoV-2 coronavirus, and the current pandemic has affected more than 80 million people and caused nearly two million deaths worldwide. The SARS-CoV-2 virus attaches to angiotensin-converting enzyme 2 (ACE2) receptors on the host cell membrane, with the help of dipeptidyl peptidase 4 (DPP4), both exopeptidases.1 Cleavage of the virus spike protein (S-protein) by endopeptidases, such as transmembrane protease, serine 2 (TMPRSS2) and furin, occurs following which the virus enters the host cell leading to virus replication.1 Other enzymes, such as the sialyltransferases, ST6GAL1 and ST3GAL4, play a role for the synthesis of influenza A virus entry receptors 2; however, their role in SARS-CoV-2 infection has not been elucidated. Asthma is a chronic inflammatory airway disease affecting 350 million people worldwide. It has not been linked to serious outcomes when presenting with COVID-19 infection, although a higher risk of death has been reported in severe asthma populations.3 The heterogeneous inflammatory nature of asthma raises the possibility that the type of asthmatic inflammation might determine the outcome of SARS-CoV-2 infection in asthma. Type 2 (T2) inflammatory markers have been associated with decreased ACE2 expression in asthma4, 5 that could underlie the reduced risk of SARS-CoV-2 infection in asthmatics. In contrast, non-T2 asthma, particularly neutrophilic asthma, has been associated with higher ACE2 and endopeptidases (TMPRSS2 and furin) expression as compared with the T2-high phenotype4, 5 that might imply a worse outcome with COVID-19 infection. Airway microbial imbalances have been reported in asthma, particularly in severe non-T2 asthma, and are characterized by decreased microbial α-diversity with increased pathogenic bacterial abundances in association with neutrophilia.6 Endopeptidases involved in S-protein cleavage such as furin may also play a role in the cleavage of pathogenic bacteria such Streptococcus pneumoniae and Pseudomonas aeruginosa or bacterial toxins.7, 8 High expression of such endopeptidases may be associated not only with a higher risk of SARS-CoV-2 infection but also with microbial imbalances in severe asthma. Therefore, the aim of this study was to investigate associations of sputum endopeptidases gene expression with metagenomics composition and whether they could be used to stratify asthma patients according to risk of SARS-CoV-2 infection. We e

Source: Allergy

DOI: 10.1111/all.14731